{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:43:25Z","timestamp":1787319805420,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Scilex Holding Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40744-025-00772-8","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T04:39:49Z","timestamp":1748839189000},"page":"721-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model"],"prefix":"10.1007","volume":"12","author":[{"given":"Jaymin","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-1542","authenticated-orcid":false,"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8380-1393","authenticated-orcid":false,"given":"Dmitri","family":"Lissin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"772_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9501","volume":"6","author":"C Yokose","year":"2023","unstructured":"Yokose C, McCormick N, Lu N, et al. Trends in prevalence of gout among US Asian adults, 2011\u20132018. JAMA Netw Open. 2023;6:e239501.","journal-title":"JAMA Netw Open"},{"key":"772_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya B, Choi H. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med. 2012;125:679\u201387.","journal-title":"Am J Med"},{"key":"772_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050046","volume":"7","author":"E Krishnan","year":"2012","unstructured":"Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009\u201310. PLoS ONE. 2012;7:e50046.","journal-title":"PLoS ONE"},{"key":"772_CR4","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1681\/ASN.2007111256","volume":"19","author":"SD Cohen","year":"2008","unstructured":"Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008;19:2204\u201310.","journal-title":"J Am Soc Nephrol"},{"key":"772_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al. American College of Rheumatology Guideline for the management of gout. Arthritis Rheumatol. 2020;72:879\u201395.","journal-title":"Arthritis Rheumatol"},{"key":"772_CR6","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64:1447\u201361.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"772_CR7","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1016\/S0021-9258(18)49931-0","volume":"266","author":"JF Diaz","year":"1991","unstructured":"Diaz JF, Andreu JM. Kinetics of dissociation of the tubulin-colchicine complex. J Biol Chem. 1991;266:2890\u20136.","journal-title":"J Biol Chem"},{"key":"772_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/clpt.1993.161","volume":"54","author":"ON Chappey","year":"1993","unstructured":"Chappey ON, Niel E, Wautier J-L, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther. 1993;54:360\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"772_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF03190118","volume":"14","author":"G Achtert","year":"1989","unstructured":"Achtert G, Scherrmann JM, Christen MO. Pharmacokinetics\/bioavailability of colchicine in healthy male volunteers. Eur J Drug Metab Pharmacokinet. 1989;14:317\u201322.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"772_CR10","first-page":"710","volume":"21","author":"E Ben-Chetrit","year":"1994","unstructured":"Ben-Chetrit E, Scherrmann JM, Zylber-Katz E, Levy M. Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol. 1994;21:710\u20133.","journal-title":"J Rheumatol"},{"key":"772_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0049-0172(91)90003-I","volume":"21","author":"C Putterman","year":"1991","unstructured":"Putterman C, Ben-Chetrit E, Caraco Y, Levy M. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Semin Arthritis Rheum. 1991;21:143\u201355.","journal-title":"Semin Arthritis Rheum"},{"key":"772_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11926-002-0073-2","volume":"4","author":"Y Molad","year":"2002","unstructured":"Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4:252\u20136.","journal-title":"Curr Rheumatol Rep"},{"key":"772_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","volume":"135","author":"PC Robinson","year":"2022","unstructured":"Robinson PC, Terkeltaub R, Pillinger MH, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135:32\u20138.","journal-title":"Am J Med"},{"key":"772_CR14","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429\u201332.","journal-title":"J Rheumatol"},{"key":"772_CR15","unstructured":"Colcrys [Package Insert]. Philadelphia, PA; Mutual Pharmaceutical Company, Inc.; 2009."},{"key":"772_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-020-2120-7","volume":"22","author":"S Stewart","year":"2020","unstructured":"Stewart S, Yang K, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22:28.","journal-title":"Arthritis Res Ther"},{"issue":"S2","key":"772_CR17","first-page":"14","volume":"9","author":"J Yin","year":"2020","unstructured":"Yin J, Vishnupad N, Willett M, et al. Pharmacokinetic study of colchicine oral solution (0.6\u00a0mg) and exposure comparison with probenecid\/colchicine tablets USP under fasted and fed conditions in healthy adult subjects. Poster Number: 020. Clin Pharmacol Drug Dev. 2020;9(S2):14\u20135.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"772_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","volume":"34","author":"S Wason","year":"2014","unstructured":"Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34:845\u201355.","journal-title":"Clin Drug Investig"},{"key":"772_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/00498254.2021.1909782","volume":"51","author":"E Karatza","year":"2021","unstructured":"Karatza E, Ismailos G, Karalis V. Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens. Xenobiotica. 2021;51:643\u201356.","journal-title":"Xenobiotica"},{"key":"772_CR20","first-page":"419","volume":"7","author":"K Srivastava","year":"2013","unstructured":"Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adher. 2013;7:419\u201334.","journal-title":"Patient Prefer Adher"},{"issue":"4","key":"772_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/BF00194404","volume":"46","author":"M Rochdi","year":"1994","unstructured":"Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol. 1994;46(4):351\u20134.","journal-title":"Eur J Clin Pharmacol"},{"key":"772_CR22","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"R Terkeltaub","year":"2010","unstructured":"Terkeltaub R, Furst D, Bennett K, Kook K, Crockett RS, Davis WM. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060\u20138.","journal-title":"Arthritis Rheum"},{"key":"772_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","volume":"38","author":"RA Terkeltaub","year":"2009","unstructured":"Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"772_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","volume":"23","author":"HL Pisaniello","year":"2021","unstructured":"Pisaniello HL, Fisher MC, Farquhar H, et al. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. Arthritis Res Ther. 2021;23:130.","journal-title":"Arthritis Res Ther"},{"key":"772_CR25","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.34067\/KID.0000000000000221","volume":"4","author":"V Kannuthurai","year":"2023","unstructured":"Kannuthurai V, Gaffo A. Management of patients with gout and kidney disease: a review of available therapies and common missteps. Kidney360. 2023;4:e1332\u201340.","journal-title":"Kidney360"},{"key":"772_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","volume":"17","author":"LK Stamp","year":"2021","unstructured":"Stamp LK, Farquhar H, Pisaniello HL, et al. Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities. Nat Rev Rheumatol. 2021;17:633\u201341.","journal-title":"Nat Rev Rheumatol"},{"key":"772_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","volume":"70","author":"AB Vargas-Santos","year":"2017","unstructured":"Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017;70:422\u201339.","journal-title":"Am J Kidney Dis"},{"key":"772_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semarthrit.2012.03.013","volume":"42","author":"RV Curiel","year":"2012","unstructured":"Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum. 2012;42:166\u201378.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00772-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00772-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00772-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:48:12Z","timestamp":1757177292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00772-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00772-8","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jaymin Shah is a consultant to Scilex Holding Company. Michael H. Pillinger is a consultant for Amgen, Fortress Bioscience, Convergence Bio and Federation Bio and has received investigator-initiated grants paid to NYU Grossman School of Medicine from Hikma Pharmaceuticals and Horizon Pharma. Elaine K. Chan and Dmitri Lissin are employees of Scilex Holding Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}